Optical Prism September 2019 | Page 32

Special Feature BRIAN PALL Director of Clinical Science at Johnson & Johnson Vision Care J&J Vision developing potential new category of contacts By Denis Langlois Johnson & Johnson Vision is working to develop an antihistamine- releasing contact lens that’s aimed at correcting vision, while reducing eye itch from allergies. Phase 3 clinical study results, published in the journal Cornea, have demonstrated that patients wearing the investigational contact lens - daily disposable lenses containing ketotifen, a drug that inhibits certain substances that are known to cause allergic reactions and inflammation - had lower mean itching scores after their eyes were exposed to allergens compared to those wearing non-medicated control lenses. Following on the Cornea publication, additional data from an initial proof of concept study involving two different doses of the antihistamine ketotifen was presented at this year’s Association for Research in Vision and Ophthalmology annual meeting in Vancouver, B.C. This trial provided the basis for additional studies, including the Phase 3 pivotal trials which were the first large-scale studies to evaluate a contact lens-based drug delivery system. Optical Prism recently spoke with Brian Pall, Director of Clinical Science at Johnson & Johnson Vision Care and the lead author of the manuscript, about the investigational lenses and what’s next. 32 Optical Prism | September 2019 Q. Please explain the impact of ocular allergies on patients and why it is important to Johnson & Johnson Vision to find ways to help people with this condition? A. More than 20 percent of the population experience ocular allergy, or itchy eyes, and the condition can have a significant impact on productivity or quality of life. Contact lens wearers are particularly impacted by ocular allergies, so we are very pleased to have reached this important research and development milestone. The primary symptom of ocular allergy is indeed itch – with eye-rubbing causing both an exacerbation of allergic symptoms and risk to disrupting the ocular surface or damaging a person’s contact lenses. Often contact lens wearers resort to suffering through or removing their lenses which is never good if contact lenses are their preferred way to correct their vision. Given the unmet need, Johnson & Johnson Vision is continuing to develop what could be an entirely new category of contact lenses – a